Our CEO Michelle Werner chats with Tides Global about her journey leading up to being CEO at Alltrna and how her personal experiences influenced her career to advance novel therapeutics. Read more at @Informa: https://lnkd.in/g-2cBwry #rarediseases #geneticmedicines #tRNA
Alltrna’s Post
More Relevant Posts
-
The May edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month includes topics such as the corticoid-sparing capabilities of belimumab and the new SLESIS-R score: https://ow.ly/13OG50S3Mou
-
-
Discover how a comprehensive study mapped the interactome of GPCRs and RAMPs, revealing new insights into their complex interactions and potential for targeted therapeutics. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://bit.ly/3WXdBMd #gpcr #drgpcr
-
-
In this video from our National Conference, Steven Munger talks about the need for increased education on smell and taste testing. Watch the video here: https://lnkd.in/etJkNFbR Rhino Therapeutics kindly sponsored our National Conference. #SmellAndTaste #SmellAndTasteTesting #SmellAndTasteTest
-
-
Medical Oncologist, Researcher – Minsk City Clinical Oncologic Centre, ESO Ambassador
With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers
The last webinar in the #PrecisionOncology series presents ESMO’s new proposal for a classification of tissue-agnostic therapeutics. Secure your place and have your questions answered by international experts. 👉Register now with your ESMO account: 🔗https://ow.ly/G41o50R95Gk Claudia Cardone, Vivek Subbiah, Sewanti Limaye, Benedikt Westphalen, George Pentheroudakis
-
-
The start of a new year is a time to reflect on past accomplishments and future ambitions. This recently published article in the Clinical Leader shares how the FSHD Society-Fulcrum Therapeutics partnership began, how it has evolved over time, and where we hope to go in the future. You can read the whole story here: https://lnkd.in/ekCbQnqP
-
-
Welcome back to 2024! This year is gearing up to be even bigger than 2023 for Argenica Therapeutics, with Phase 2 clinical trial in acute ischaemic stroke (AIS) patients right around the corner. If you missed it, last month we provided a company update that addressed the current status of the clinical trial. ⬇ You can find the announcement here ⬇ AGN investor announcement: https://bit.ly/3NVPdWu #ASX #AGN #investor #clinicaltrial #clinicaltrialupdate #stroke #strokeawareness
-
-
Kristi Campoe, PhD, RN, CMSRN, CPHQ, sMBA
Kristi Campoe, PhD, RN, CMSRN, CPHQ, sMBA is an Influencer FemTech Leader | Board Director | Medical Device Expert | Scientist | The BOLD Nurse Coach & Consultant | MEDSURG Nurse Advocate | Author
It's not too late to attend this webinar today - Pharmacogenomics: Transforming Patient Care
Our first webinar of the year is happening tomorrow! Join us from 2 p.m. - 3 p.m. CT as we cover "Pharmacogenomics: Transforming Patient Care". This is a can't-miss session that will explore all about the basics of pharmacogenomics, implications of testing, current uses of pharmacogenomic therapeutics, and more. Register now: https://hubs.la/Q02hTJj30
-
-
Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica
-
-
Chief & Director, Cellular Therapy Program. Associate Professor, Children's National & GWU | Cell Therapy Expert | Speaker | Leader
Great to see some positive news in the allogeneic CAR T space. Especially for a disease like Multiple Myeloma where commercial companies have struggled to meet demand. Also interest to see prominent use of a non-viral gene delivery platform, which I think we'll see more of very soon. #CART #celltherapy #genetherapy.
More positive #CARTcellTherapy news for #MultipleMyeloma patients as Poseida Therapeutics, Inc. and Roche's allogeneic product advances in clinical setting with a reported 91% ORR in 23 patients. (From geneng news) https://lnkd.in/guDcJxjP
-
-
CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials
-
